Galapagos NV gave its investors some wobbles during its R&D day in New York Tuesday, revealing that its first-in-class, free fatty acid receptor 2 (FFA2) inhibitor, GLPG974, failed to demonstrate clinical benefit in ulcerative colitis and that recruitment delays will push back top-line data from two phase IIb trials of selective JAK1 inhibitor GLPG634 in rheumatoid arthritis patients.